biotech · Neuroblastoma · Hyperinflammation, Sepsis · AXIM
AXIM Biotechnologies
AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies clinical programs — 20 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 18 East 50th Street, 5 Floor, New York, NY 10022, US
- Founded
- 2011
- Employees
- 7
- Programs
- 20
- Drugs
- 52
- Patents
- 138
AXIM Biotechnologies projects
20 ClinicalTrials.gov programs sponsored by AXIM Biotechnologies.
AXIM Biotechnologies has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
INFLUENCE
AXIM BIOTECHNOLOGIES, INC.
B-cell Acute Lymphoblastic Leukemia
1 trial -
IVEMEND for Delayed chemotherapy induced na…
AXIM BIOTECHNOLOGIES, INC.
Delayed chemotherapy induced nausea and vomiting (CINV)
1 trial -
SP_MH19PRO
AXIM BIOTECHNOLOGIES, INC.
Acute myeloid leukemia
1 trial -
ANAKINRA
AXIM BIOTECHNOLOGIES, INC.
Hyperinflammation, Sepsis
1 trial -
Anti-GD2-800CW
AXIM BIOTECHNOLOGIES, INC.
Neuroblastoma
1 trial -
BrigaPED ITCC-098
AXIM BIOTECHNOLOGIES, INC.
Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors
1 trial -
HEM-iSMART - Sub B
AXIM BIOTECHNOLOGIES, INC.
Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
1 trial -
HEM-iSMART sub C
AXIM BIOTECHNOLOGIES, INC.
Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
1 trial -
IOBENGUANE (123I) , 68Ga-SSO120
AXIM BIOTECHNOLOGIES, INC.
neuroblastoma
1 trial -
MB-huCART19.1
AXIM BIOTECHNOLOGIES, INC.
B-cell precursor ALL, B-cell Non Hodgkin Lymphoma
1 trial -
ONC201, Paxalisib
AXIM BIOTECHNOLOGIES, INC.
Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)
1 trial -
PS22PET
AXIM BIOTECHNOLOGIES, INC.
(suspision on) Neuroblastoma
1 trial -
Quizartinib
AXIM BIOTECHNOLOGIES, INC.
newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
1 trial -
SIOPEN-Pilot01
AXIM BIOTECHNOLOGIES, INC.
Neuroblastoma
1 trial -
Tovorafenib, Tovorafenib
AXIM BIOTECHNOLOGIES, INC.
craniopharyngioma
1 trial -
Chewing Gum
AXIM BIOTECHNOLOGIES, INC.
THC
1 trial -
ONC206 Powder
AXIM BIOTECHNOLOGIES, INC.
Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
1 trial -
SP_MH20VYX
AXIM BIOTECHNOLOGIES, INC.
AML
1 trial -
WT1-loaded CBDC Vaccine
AXIM BIOTECHNOLOGIES, INC.
AML: Acute Myeloid Leukemia/ cancer of blood and bone marrow
1 trial -
Ziftomenib for Acute Myeloid Leukemia, Mixed P…
AXIM BIOTECHNOLOGIES, INC.
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia
1 trial
Frequently asked questions
How many clinical projects does AXIM Biotechnologies have?
20 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.